IREN proposes $875 million convertible notes offering due 2031
Kura Oncology (NASDAQ:KURA) President and CEO Troy Edward Wilson sold 36,615 shares of common stock on September 29, 2025, at a price of $8.9422, totaling $327,418. The transaction comes as the stock has shown strong momentum, gaining nearly 11% in the past week and trading near $9. InvestingPro analysis shows the company maintains a healthy balance sheet with more cash than debt.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was to cover taxes associated with the vesting of performance-based restricted stock units. On September 27, 2025, Wilson also acquired 182,500 shares of Common Stock at $0. With a market capitalization of approximately $777 million, analysts maintain a bullish stance on KURA, with price targets ranging from $11 to $40. Get comprehensive insider trading analysis and 12 additional key insights with InvestingPro.
In other recent news, Kura Oncology reported its second-quarter 2025 financial results, which showed a significant shortfall in revenue expectations. The company generated $15.3 million in revenue, falling short of the forecasted $39.1 million by 60.88%. Additionally, Kura Oncology’s earnings per share (EPS) were below projections, with a reported loss of $0.75 compared to the expected loss of $0.41. In response to these developments, Citizens JMP lowered its price target for Kura Oncology to $24.00 from $28.00, although it maintained a Market Outperform rating on the stock. Meanwhile, Guggenheim initiated coverage on Kura Oncology with a Neutral rating, pointing to challenges in the upcoming launch of ziftomenib for treating relapsed/refractory NPM1-mutated acute myeloid leukemia. Kura Oncology plans to present preliminary clinical data for its next-generation farnesyl transferase inhibitor, KO-2806, also known as darlifarnib, at an upcoming medical congress. The company has highlighted the potential of darlifarnib to enhance the effectiveness of targeted cancer therapies by addressing resistance mechanisms. Citizens JMP reiterated its positive outlook on Kura Oncology, emphasizing the potential of KO-2806 in overcoming resistance to targeted therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.